NEUP
NASDAQ · Biotechnology
Neuphoria Therapeutics Inc
$4.88
-0.21 (-4.13%)
Open$5.11
Previous Close$5.09
Day High$5.11
Day Low$4.68
52W High$21.40
52W Low$3.65
Volume—
Avg Volume23.2K
Market Cap27.44M
P/E Ratio—
EPS$-2.12
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+203.1% upside
Current
$4.88
$4.88
Target
$14.79
$14.79
$9.77
$14.79 avg
$16.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.22M | 5.17M | 4.87M |
| Net Income | -1,282,016 | -354,866 | -256,361 |
| Profit Margin | -2.4% | -6.9% | -5.3% |
| EBITDA | 255.8K | -507,265 | -425,609 |
| Free Cash Flow | — | -183,163 | -132,058 |
| Rev Growth | +696.2% | -7.1% | +6.1% |
| Debt/Equity | 0.00 | 0.39 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |